Clinical Trial Update: Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial update investigating dalpiciclib with fulvestrant, trastuzumab, and pertuzumab in HR-positive, HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Fulvestrant (fulvestrant)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN